Loading clinical trials...
Loading clinical trials...
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
September 11, 2024
Primary Completion Date
March 31, 2026
Completion Date
March 31, 2028
Last Updated
October 14, 2025
20
ESTIMATED participants
Lead Sponsor
M.D. Anderson Cancer Center
NCT01422694
NCT07484243
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions